REGISTER now for FREE 
|
FREE patent keyword monitoring and additional FREE benefits. REGISTER now for FREE
|
 
|
|
Drug, Bio-affecting And Body Treating Compositions > Designated Organic Active Ingredient Containing (doai) > Heterocyclic Carbon Compounds Containing A Hetero Ring Having Chalcogen (i.e., O,s,se Or Te) Or Nitrogen As The Only Ring Hetero Atoms Doai > Hetero Ring Is Six-membered Consisting Of One Nitrogen And Five Carbon Atoms > Polycyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Bicyclo Ring System Having The Six-membered Hetero Ring As One Of The Cyclos > Plural Hetero Atoms In The Bicyclo Ring System Plural Hetero Atoms In The Bicyclo Ring SystemPlural Hetero Atoms In The Bicyclo Ring System patent applications listed are from June 2005 to current and include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.02/01/07 - 20070027179 - Azaindole derivatives, preparations thereof, uses thereof and compositions containing them Compounds of formula I or pharmaceutically acceptable salts thereof Formula (I) wherein Ar, R1, R2, R3, Ra, Rb and X are as defined in the specificationas well as salts and pharmaceutical compositions including the compounds are prepared. They are useful in therapy, in particular in the management of pain. ... 01/18/07 - 20070015786 - Treatment of hot flashes, impulse control disorders and personality change due to a general medical condition Selective norepinephrine reuptake inhibitors are useful for the prevention or treatment of hot flashes, vasomotor symptoms, impulse control disorders or personality change due to a general medical condition. ... 01/04/07 - 20070004769 - Intermediate products for producing oxazolidinone-quinolone hybrids The present invention describes intermediates (ZP) for a novel and efficient synthesis of compounds in which the pharmacophores of quinolone and oxazolidinone are linked to one another by way of a chemically stable linker. ... 12/21/06 - 20060287354 - Azaindole compounds as kinase inhibitors The present invention relates to novel azaindole compounds which are kinase inhibitors, methods for their preparation intermediates and pharmaceutical compositions comprising them. ... 12/14/06 - 20060281779 - 7-(4-substituted-3-cyclopropylaminomethyl-1 pyrrolidinyl) quinolonecarboxylic acid derivative There are provided 7-(4-substituted-3-cyclopropylaminomethylpyrrolidinyl)quinolonecarboxylic acid derivatives (such as 1-cyclopropyl-7-[(3S,4S)-3-cyclopropylaminomethyl-4-fluoro-1-pyrrolidinyl]-6-fluoro-1,4-dihydro-8-methoxy-4-oxo-3-quinolinecarboxylic acid) that exhibit strong antibacterial activity against gram-positive bacteria, such as MRSA, PRSP and VRE, while being safe. The compounds are shown by the following general formula (I): ... 12/07/06 - 20060276498 - 4,6-diamino-[1,7]naphthyridine-3-carbonitrile inhibitors of tpl2 kinase and methods of making and using the same and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, R5, R6, m and n are defined as described herein. The invention also provides methods of making the compounds of formula (I), and methods of treating inflammatory diseases, such as rheumatoid arthritis, in a mammal comprising administering a therapeutically effective ... 11/30/06 - 20060270703 - G-csf conjugates The invention relates to polypeptide conjugates comprising a polypeptide exhibiting G-CSF activity and having an amino acid sequence that differs from the amino acid sequence of human G-CSF in at least one specified introduced and/or removed amino acid residue comprising an attachment group for a non-polypeptide moiety, and having at ... 11/30/06 - 20060270702 - Certain substituted ureas, as modulators of kinase activity Certain chemical entities chosen from compounds of Formula 1 and pharmaceutically acceptable salts, solvates, chelates, non-covalent complexes, and prodrugs thereof, are provided herein. Pharmaceutical compositions comprising at least one chemical entity and one or more pharmaceutically acceptable vehicles chosen from carriers, adjuvants, and excipients, are also provided herein. Methods of ... 11/30/06 - 20060270701 - Dipeptidyl peptidase-iv inhibitors The present invention relates generally to pyrrolidine and thiazolidine DPP-IV inhibitor compounds. The present invention also provides synthetic methods for preparation of such compounds, methods of inhibiting DPP-IV using such compounds and pharmaceutical formulations containing them for treatment of DPP-IV mediated diseases, in particular, Type-2 diabetes. ... 11/23/06 - 20060264457 - Pyrrolopyridine-based inhibitors of dipeptidyl peptidase iv and methods wherein R, X, Y, Z, A and n are as defined herein, which are inhibitors of dipeptidyl peptidase IV and thus are useful in treating diabetes and related diseases. ... 11/16/06 - 20060258700 - 7-azaindoles, their use as inhibitors of phosphodiesterase 4, and a method for synthesizing them 7-azaindoles inhibit phosphodiesterase 4 (PDE4). Methods for preparing these compounds are also provided. ... 11/09/06 - 20060252789 - Amorphous moxifloxacin hydrochloride The invention relates to an amorphous form of moxifloxacin hydrochloride and processes for preparing amorphous moxifloxacin hydrochloride. The invention also relates to pharmaceutical compositions that include the amorphous moxifloxacin hydrochloride and use of said compositions for the treatment of bacterial infections. ... 11/02/06 - 20060247267 - Sns-595 and methods of using the same The present invention relates to SNS-595 and methods of treating cancer using the same. ... 10/19/06 - 20060235042 - Synthesis The present invention provides a novel substituted azaindoline intermediate of formula (I) and a method for its synthesis. The novel substitued azaindoline intermediate (I) is provided for use in the manufacture of 5-substituted 7-azaindolines and 5-substituted 7-azaindoles. ... 10/05/06 - 20060223843 - Substituted 1,5-naphthyridine azolinones Substituted 1,5-naphthyridine azolinones inhibit Cdk1 and are selective against Cdk2 and Cdk4. These compounds and their pharmaceutically acceptable salts have antiproliferative activity and are useful as anti-cancer agents. ... 10/05/06 - 20060223842 - 2-aryl-acetic acids, their derivatives and pharmaceutical compositions containing them Selected 2-arylacetic acids, their derivatives and pharmaceutical compositions that contain these compounds are useful in inhibiting chemotactic activation of neutrophils (PMN leukocytes) induced by the interaction of Interleukin-8 (IL-8) with CXCR1 and CXCR2-membrane receptors. The compounds are used for the prevention and treatment of pathologies deriving from said activation. In ... 09/28/06 - 20060217413 - 4-oxoquinoline compound and use thereof as hiv integrase inhibitor wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such ... 09/21/06 - 20060211728 - Thalidomide analogs Thalidomide analogs that modulate tumor necrosis factor alpha (TNF-α) activity and angiogenesis are disclosed. In particularly disclosed embodiments, the thalidomide analogs are isosteric sulfur-containing analogs. Also disclosed are methods of treating a subject with the analogs. ... 09/21/06 - 20060211727 - Novel compounds Novel substituted 1,5,7-trisubstituted-1,8-napthyridin-2(1H)-one compounds; 1,5,7 trisubstituted-1,6-napthyridine-2-(1H)-one compounds and 1,5,7-trisubstituted quinoline-2(1H)-one compounds, processes for the preparation thereof, the use thereof in treating CSBP/p38 kinase mediated diseases and pharmaceutical compositions for use in such therapy. ... 09/14/06 - 20060205763 - Substituted pyrroline kinase inhibitors The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder. ... 09/14/06 - 20060205762 - Substituted pyrroline kinase inhibitors The present invention is directed to novel substituted pyrroline compounds useful as kinase inhibitors and methods for treating or ameliorating a kinase mediated disorder. ... 09/14/06 - 20060205761 - Ccr-2 antagonists for treatment of neuropathic pain The invention is directed to methods of treating neuropathic pain and other neuropathic diseases and conditions with CCR-2 antagonists and pharmaceutical composition containing CCR-2 antagonists. ... 09/07/06 - 20060199835 - Neuroprotective and anti-proliferative compounds This invention features compounds of formula (I), (II) and (III), which are useful in the treatment of proliferative disorders characterized by loss of growth or cellular differentiation control including, but not limited to, cancer and inflammation. Formulas (I), (II), (III) have functional groups designated as A1, A2, B1, B2, X1—X9 ... 08/31/06 - 20060194830 - Method for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone) The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone. ... 08/24/06 - 20060189647 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof wherein R1, R2, R3, R4 and R5 are as defined herein for Formula (IA), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized ... 08/24/06 - 20060189646 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof wherein R1, R2, R3, R4, R5, R6, and R7 are as defined herein, or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the glucocorticoid receptor function or characterized by ... 08/03/06 - 20060173035 - 3-aryloxy/thio-2,3-substituted propanamines and their use in inhibiting serotonin and norepinephrine reuptake There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from phenyl optionally substituted with up to 5 substituents each independently selected from halo, C1-C4 alkyl and C1-C4 alkoxy, thienyl optionally substituted with up to 3 substituents each independently selected from ... 07/27/06 - 20060167038 - Pyrrolopyridine derivative and use thereof wherein Ring A represents an optionally substituted pyridine ring; X represents an electron-attracting group; Y represents an optionally substituted divalent C1-6 chain hydrocarbon group; R1 represents an optionally substituted hydrocarbon group; and R2 and R3 each independently represents hydrogen, an optionally substituted hydrocarbon group or an optionally-substituted heterocyclic group, or ... 07/13/06 - 20060154956 - Bicyclic heterocycles as cannabinoid receptor modulators including all prodrugs, pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R3a, R4, A, B, b, n, W, X, Y and Z are described herein. ... 07/13/06 - 20060154955 - Bicyclic heterocycles as cannabinoid receptor modulators including all pharmaceutically acceptable salts and stereoisomers, R1, R2, R3, R3a, R4, n, Y and Z are described herein. ... 06/29/06 - 20060142324 - Aryl fused 2,4-disubstituted pyridines: nk3 receptor ligands Disclosed are compounds of formula (I) or pharmaceutically acceptable non-toxic salts or pharmaceutically acceptable solvates thereof wherein: (II) represents (a), (b), (c) or (d) and W, X, Y, A, B, C, D, E are variables as described herein. These compounds are highly selective agonists or antagonists at NK3 receptors or ... 06/22/06 - 20060135551 - Novel heterocyclic compounds and their pharmaceutical compositions The present invention provides, among other things, new bicyclic heterocyclic compounds, compositions comprising these heterocyclic compounds, methods of making the heterocyclic compounds, and methods of using these heterocyclic compounds for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism. ... 06/15/06 - 20060128746 - Methods, kits and compositions for using pyrrole derivatives The present invention also provides compositions comprising a compound of Formula I or a pharmaceutically acceptable salt, optical isomer or prodrug thereof and an additional compound useful to treat the aforementioned conditions. ... 06/15/06 - 20060128745 - Chemical compounds The present invention is related to aza-oxindole derivatives, compositions containing the same, and methods of use and manufacture of the same. Such compounds generally are useful pharmacologically as agents in those disease states alleviated by the alteration of mitogen activated signaling pathways in general, and in particular in the inhibition ... 06/15/06 - 20060128744 - Use of 5-ht6 agonist for the treatment and prevention of neurodegenerative disorders The present invention provides method for the treatment, amelioration or prevention of a neurodegenerative disorder in a patient in need thereof which comprises administering to said patient an effective amount of a 5-hydroxytryptamine-6 agonist. ... 06/08/06 - 20060122215 - Preparation and use of 1,5,6,7-tetrahydropyrrolo[3,2-c]pyridine derivatives for the treatment of obesity This invention relates to 1,5,6,7-tetrahydropynolo[3,2-c]pyridine derivatives which have been found to suppress appetite and induce weight loss. The invention also provides methods for synthesis of the compounds, pharmaceutical compositions comprising the compounds, and methods of using such compositions for inducing weight loss and treating obesity and obesity-related disorders. ... 06/08/06 - 20060122214 - Agent for prophylaxis and treatment of angiostenosis An agent for the prophylaxis and treatment of vascular constriction is provided, which contains a compound having a Rho kinase inhibitory activity. In particular, a compound having a Rho kinase inhibitory activity, for example, (+)-trans-4-(1-aminoethyl)-1-(4-pyridylcarbamoyl)cyclohexane, suppresses regenerative intima proliferation after disorder of blood vessel and has various other actions. Therefore, ... 06/08/06 - 20060122213 - Azaindoles useful as inhibitors of protein kinases The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing the compounds of the invention. ... 06/08/06 - 20060122212 - Bicyclic heteroaromatic compounds as kinase inhibitors A series of 5-6 fused ring bicyclic heteroaromatic derivatives, based in particular on the 5-oxo-4,5-dihydro-1H-pyrrolo[3,2-b]pyridine ring system, being inhibitors of p38 kinase, are accordingly of use in medicine, for example in the treatment and/or prevention of immune or inflammatory disorders. ... 06/01/06 - 20060116394 - Fab i inhibitors Compounds are disclosed which are Fab I inhibitors and are useful in the treatment bacterial infections. ... 05/25/06 - 20060111392 - Substituted biaryl-carboxylate derivatives Substituted biaryl-carboyxlate derivatives are bradykinin B1 antagonists or inverse agonists useful in the treatment or prevention of symptoms such as pain and inflammation associated with the bradykinin B1 pathway. ... 05/25/06 - 20060111391 - Pyridine imidazoles and aza-indoles as progesterone receptor modulators The present invention is directed to novel heteroatom containing tetracyclic derivatives, pharmaceutical compositions containing them and their use in the treatment of disorders mediated by one or more estrogen receptors. The compounds of the invention are useful in the treatment of disorders associated with the depletion of estrogen such as ... 05/25/06 - 20060111390 - Azaindoles as inhibitors of c-jun n-terminal kinases The present invention relates to novel 5-substituted 7-azaindole compounds of formula (I), their use in the inhibition of c-Jun N-terminal kinases, their use in medicine and particularly in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation. The invention also provides processes for manufacture of said compounds, ... 05/11/06 - 20060100230 - Indolin phenylsulfonamide derivatives The invention relates to novel substituted indolin phenylsulfonamide derivatives, to a method for the production thereof and to the use thereof in medicaments, especially as potent PPAR-delta activating compounds for the prophylaxis and/or treatment of cardiovascular diseases, especially dyslipidaemia and coronary heart diseases. ... 05/04/06 - 20060094747 - Substituted carboxylic acids which are useful in the treatment of metabolic disorders related to insulin resistance or hyperglycemia. These compounds include inhibitors of protein tyrosine phosphatase (PTP-1B) that are useful in the treatment of diabetes and other PTP-1B mediated diseases, such as cancer, neurodegenerative diseases and the like. The compounds of the invention ... 04/20/06 - 20060084673 - 1,5-naphthyridine azolinone 1,5-Naphthyridine azolinone derivatives are disclosed. These compounds are inhibitors of CDK1 and are useful as antiproliferative agents, such as anti-cancer agents. ... 04/13/06 - 20060079546 - Aminopiperidine derivatives as antibacterials Aminopiperidine derivatives of Formula (I) and pharmaceutically acceptable derivatives thereof useful in methods of treatment of bacterial infections in mammals, particularly in man: ... 03/30/06 - 20060069115 - Use of pde4 inhibitors as adjunct therapy for psychiatric disorders The use of a PDE4 inhibitor in conjunction with psychotherapy provides enhanced therapeutic results in the treatment of psychiatric disorders including, for example, specific phobias, panic disorders, anxiety disorders including posttraumatic stress disorders, and obsessive-compulsive disorder. ... 03/23/06 - 20060063796 - Pyrazoles as inhibitors of tumor necrosis factor and ester prodrugs, pharmaceutically acceptable salts or solvates of such compounds; or ester prodrugs of such salts or solvates; pharmaceutical compositions comprising such compounds, their preparation, and their pharmaceutical use in the treatment of disease states capable of being modulated by the inhibition of p38 kinase and/or tumor necrosis factor ... 03/23/06 - 20060063795 - Sns-595 and methods of using the same The present invention relates to SNS-595 and methods of treating cancer using the same. ... 03/16/06 - 20060058340 - Compounds modulating c-kit activity Compounds with 7-azaindole core structure with activity toward the receptor protein tyrosine kinase c-kit, compositions useful for treatment c-kit-mediate diseases or conditions, and methods of use thereof, are provided. Further provided are methods of c-kit ligand identification and design. ... 03/16/06 - 20060058339 - Compounds modulating c-kit activity and uses therefor Compounds with generic structure 5-((1H-pyrrolo[2,3-b]pyridin-3-yl)methyl)-N-benzylpyridine-2-amine with activity toward the receptor protein tyrosine kinase c-kit, compositions useful for treatment c-kit-mediate diseases or conditions, and methods of use thereof are described. ... 03/16/06 - 20060058338 - [1,7]naphthyridines as pde4 inhibitors in free or salt form, wherein R1, R2 and R3 have the meanings as indicated in the specification, are useful for treating conditions mediated by of phosphodiesterase type 4 or the down-regulation or inhibition of TNF-α release, particularly obstructive or inflammatory airways diseases. Pharmaceutical compositions that contain the compounds and ... 03/09/06 - 20060052411 - Pyridone derivatives having a binding activity to the cannabinoid type 2 receptor wherein R1 is a group represented by the formula: —Y1—Y2—Y3—Ra wherein Y1 is single bond or the like; Y2 is —C(═O)—NH— or the like; Y3 is optionally substituted aryl or the like; R2 is hydrogen or the like; R3 is alkyl or the like; R4 is alkyl or the like; ... 02/09/06 - 20060030584 - 2,8-disubstituted naphthyridine derivatives and pharmaceutically acceptable salts thereof, wherein R1, R2, R2′, R3, R21, A1, A2, X, and Z are as defined herein. Compounds of formula A are useful in the treatment of diseases and/or conditions related to cell differentiation, such as cancer, inflammation, arthritis, angiogenesis, or the like. Also disclosed are pharmaceutical ... 02/09/06 - 20060030583 - Pyrrolo-pyridine kinase modulators The present invention provides novel pyrrolo-pyridine kinase modulators and methods of using the novel pyrrolo-pyridine kinase modulators to treat diseases mediated by kinase activity. ... 02/09/06 - 20060030582 - Tetrahydropyranyl cyclopentyl tetrahydropyridopyridine modulators of chemokine receptor activity I (wherein R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, X, n and the dashed line are defined herein) which are useful as modulators of chemokine receptor activity. In particular, these compounds are useful as modulators of the chemokine receptor CCR-2. ... 02/09/06 - 20060030581 - Mannitol formulation for integrin receptor antagonist Disclosed are pharmaceutical compositions of an integrin αvβ3 receptor antagonist containing mannitol as the binding agent. The compositions are prepared by wet granulation or direct compression tablet formulation. These pharmaceutical formulations are useful for inhibiting bone resorption associated with osteoporosis, metastatic bone disease, hypercalcemia of malignancy, and Paget's disease. ... 02/02/06 - 20060025437 - Sns-595 and methods of using the same The present invention relates to SNS-595 and methods of treating cancer using the same. ... 01/26/06 - 20060019981 - Method of preparing inhibitors phosphodiesterase-4 In one aspect, the present invention is directed to a one pot method of preparing intermediates of Formula (V), which are useful in making inhibitors of phosphodiesterase-4: The present invention is also directed to a method of preparing phosphodiesterase inhibitors comprising the Formula (IX, IXa) ... 01/19/06 - 20060014779 - 3-aryloxy/thio-3-substituted propanamines and their use in inhibiting serotonin and norephinephrine reuptake There is provided a compound of formula (I) wherein A is selected from —O— and —S—; X is selected from C2-C8 alkyl, C2-C8 alkenyl, C3-C8 cycloalkyl and C4-C8 cycloalkylalkyl, each of which may be optionally substituted with up to 3 substituents each independently selected from halo, C1-C4 alkyl, C1-C4 alkoxy, ... 01/12/06 - 20060009484 - Novel polycyclic compounds which modulate ppargamma type receptors and cosmetic/pharmaceutical compositions comprised thereof are formulated into pharmaceutical compositions suited for administration in human or veterinary medicine (in dermatology, and also in the fields of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or, alternatively, into cosmetic compositions. ... 01/12/06 - 20060009483 - Compounds and compositions for the treatment of diabetes and diabetes-related disorders The present invention relates to novel compounds which are useful in the treatment of diabetes and diabetes-related disorders. The invention also relates to pharmaceutical compositions comprising said compounds, intermediates useful in the preparation of said compounds, and methods of preparation. ... 12/29/05 - 20050288322 - Methods for making 2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2oxo-hexyl)-1-isoidolinone The present invention relates to methods for making racemic 2-(7-chloro-1,8-naphthyridin-2-yl)-3-(5-methyl-2-oxohexyl)-1-isoindolinone and (+)-2-(7-chloro-1,8-naphthyridine-2-yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone. ... 12/29/05 - 20050288321 - Kinase inhibitors The present invention provides kinase inhibitors of Formula (I). ... 12/15/05 - 20050277662 - Inhibitors of the hiv integrase enzyme The present invention is directed to compounds of formula (I), and pharmaceutically acceptable salts and solvates thereof, their synthesis, and their use as modulators or inhibitors of the human immunodeficiency virus (“HIV”) integrase enzyme. ... 12/08/05 - 20050272761 - 7-azaindoles as inhibitors of c-jun n-terminal kinases for the treatment of neurodegenerative disorders The present invention relates to novel 3,5-substituted 7-azaindole compounds of formula (I), their use in the inhibition of c-Jun N-terminal kinases, their use in medecine and particularly in the prevention and/or treatment of neurodegenerative disorders related to apoptosis and/or inflammation. The invention also provides processes for manufacture of said compounds, ... 12/01/05 - 20050267146 - 3-(4-heteroarylcyclohexylamino)cyclopentanecarboxamides as modulators of chemokine receptors which are modulators of chemokine receptors. The compounds of the invention, and compositions thereof, are useful in the treatment of diseases related to chemokine receptor expression and/or activity. ... 11/24/05 - 20050261332 - Sulfonamides and uses thereof and methods of treating disorders by administering a compound of formula (I), (II), (III), or (IV) are described herein. Examples of disorders include neoplastic disorders, fat-cell related disorders, neurodegenerative disorders, and metabolic disorders. ... 11/24/05 - 20050261331 - Substituted pyrrolopyridines There are provided novel compounds of formula (I) wherein R1, R2 and R3 are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the kinase Itk. ... 11/17/05 - 20050256151 - Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune ... 11/03/05 - 20050245565 - Diamine derivatives The compound is useful as an agent for preventing and/or treating cerebral infarction, cerebral embolism, myocardial infarction, angina pectoris, pulmonary infarction, pulmonary embolism, Buerger's disease, deep venous thrombosis, disseminated intravascular coagulation syndrome, thrombus formation after valve or joint replacement, thrombus formation and reocclusion after angioplasty, systemic inflammatory response syndrome (SIRS), ... 10/27/05 - 20050239820 - Bicyclic heterocycles as kinase inhibitors The compounds of the instant invention can be used as anticancer agents. More specifically, the invention comprises a compound having Formula I or II, ... 10/27/05 - 20050239819 - 4-oxoquinoline compounds and utilization thereof as hiv integrase inhibitors wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof. The compound of the present invention has HIV integrase inhibitory action and is useful as an anti-HIV agent for the prophylaxis or therapy of AIDS. Moreover, by a combined use with other anti-HIV agents such ... 10/20/05 - 20050234091 - Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof wherein R1, R2, R3, R4, R5, R6 and X are as defined herein for Formula (IA) and Formula (IB), or a tautomer, prodrug, solvate, or salt thereof; pharmaceutical compositions containing such compounds, and methods of modulating the glucocorticoid receptor function and methods of treating disease-states or conditions mediated by the ... 10/20/05 - 20050234090 - Modulators of chemokine receptor activity Chemokine receptor antagonists, in particular, bicyclic diamine compounds of Formula (I) that act as antagonists of chemokine CCR2 and CCR3 receptors including pharmaceutical compositions and uses thereof to treat or prevent diseases associated with monocyte accumulation, lymphocyte accumulation or leucocyte accumulation are described herein. ... 10/20/05 - 20050234089 - Anti-infective agents and/or immunomodulators used for preventive therapy following an acute cerebrovascular accident The invention refers to agents for the preventive therapy after acute stroke, in particular having the aim to prevent infections after stroke. The agents inventively employed in pharmaceutical preparations are anti-infective agents and/or immunomodulating agents, e.g. cytokines and/or inhibitors of the SNS. ... 10/13/05 - 20050228011 - Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, n, i, j and k are defined herein. ... 10/06/05 - 20050222195 - Anti-constipation composition where X1 and X2 are preferably both fluorine atoms. The composition can be used to treat constipation without substantive side-effects, such as stomachache. ... 09/29/05 - 20050215583 - Sns-595 and methods of using the same The present invention relates to SNS-595 and methods of treating cancer using the same. ... 09/29/05 - 20050215582 - Substituted pyrrolopyridines There are provided novel compounds of formula (I) wherein R1, R2 and R3 are as defined in the specification and pharmaceutically acceptable salts thereof; together with processes for their preparation, compositions containing them and their use in therapy. The compounds are inhibitors of the kinase Itk. ... 09/22/05 - 20050209269 - Pyrrolo[2,3-b]pyridine derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them Compounds which are pyrrolo[2,3-b]pyridine derivatives or pharmaceutically acceptable salts thereof, their preparation process and pharmaceutical compositions comprising them are disclosed; these compounds are useful in the treatment of diseases caused by and/or associated with an altered protein kinase activity such as cancer, cell proliferative disorders, Alzheimer's disease, viral infections, auto-immune ... 09/15/05 - 20050203120 - Sns-595 and methods of using the same The present invention relates to SNS-595 and methods of treating cancer using the same. ... 09/15/05 - 20050203119 - Dihydropyridine compounds for treating or preventing metabolic disorders or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein A2, R12, R13, R14, R15, R16, R17, R18, R19, R20, R21, R22, and m are defined herein, and compositions comprising such compounds. The invention also relates to methods of preventing or treating metabolic disorders, such as diabetes mellitus, and ... 08/18/05 - 20050182087 - Cycloalkyl-substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes. ... 08/18/05 - 20050182086 - Heterocyclically substituted 7-amino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes. ... 08/18/05 - 20050182085 - 7-phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments in which the radicals have the stated meanings, and to the physiologically tolerated salts thereof. The compounds are suitable for example as medicaments for the prevention and treatment of type 2 diabetes. ... // - 7-Phenylamino-4-quinolone-3-carboxylic acid derivatives, process for their preparation and their use as medicaments The invention relates to 7-phenylamino-4-quinolone-3-carboxylic acid derivatives and to the physiologically tolerated salts and physiologically functional derivatives thereof. - ... 08/11/05 - 20050176751 - Azaindolylpiperidine derivatives as antihistaminic and antiallergic agents This invention is directed to selective antagonists of H1 histamine receptors having the general formula (I); to processes for their preparation; to pharmaceutical compositions comprising them; and to their use in therapy. ... 08/04/05 - 20050171141 - Modulators of muscarinic receptors The modulator compounds described herein modulate muscarinic receptors and are useful for treating muscarinic receptor mediated diseases. ... 08/04/05 - 20050171140 - Hmg-coa reductase inhibitors and method which compounds are HMG CoA reductase inhibitors and thus are active in inhibiting cholesterol biosynthesis, modulating blood serum lipids, for example, lowering LDL cholesterol and/or increasing HDL cholesterol, and treating hyperlipidemia, dyslipidemia, hypercholesterolemia, hypertriglyceridemia and atherosclerosis as well as Alzheimer's disease and osteoporosis and may be employed as hormone replacement ... 07/21/05 - 20050159442 - Protein tyrosine phosphatase 1b (ptp-1b) inhibitors and methods of using the same or an optical isomer, enantiomer, diastereomer, racemate or racemic mixture thereof, ester, prodrug or metabolite form, or a pharmaceutically acceptable salt thereof, wherein R1, R2 and/or R3 are independently hydrogen atoms or alkyl groups and G1 and G2 are aryl, heteroaryl, alkyl, arylalkanyl, arylalkenyl, arylalkynyl, heteroarylalkanyl, heteroarylalkenyl, or heteroarylalkynyl moieties. ... 07/07/05 - 20050148622 - Process for preparing acid salts of gemifloxacin The present invention relates to a process for preparing acid salts of Gemifloxacin, a quinolone type antibiotic agent having potent antimicrobial activity. The process according to the present invention can provide advantages such as simplicity of process, improvement of productivity and improvement of yield, and the like by reducing conventional ... 06/02/05 - 20050119296 - Substituted heteroaryl benzofuran acids The present invention relates generally to substituted heteroaryl benzofuran acids and methods of using them. ... 06/02/05 - 20050119295 - Fused heterocyclic compounds Certain fused pyrrole- and pyrazole-containing heterocyclic compounds are serotonin modulators useful in the treatment of serotonin-mediated diseases. ... ### FreshPatents.com Support - Terms & Conditions |